Testicular metastasis in prostate cancer: A rare case of testicular metastasis diagnosed with 68Ga-PSMA and review of the literature

2022 ◽  
pp. 205141582110683
Author(s):  
Gokhan Ozyigit ◽  
Bulent Akdogan ◽  
Melek Tugce Yilmaz ◽  
Gunes Guner ◽  
Murat Fani Bozkurt
Keyword(s):  
Prostate Cancer ◽  
Rare Condition ◽  
Short Review ◽  
Imaging Method ◽  
Review Of The Literature ◽  
Level Of Evidence ◽  
Testicular Metastasis ◽  
Positron Emission ◽  
Psma Pet ◽  
Pet Ct

Objective: Testicular metastasis in prostate cancer is a rare entity. We aimed to report the case where this rare condition was diagnosed with Gallium prostate-specific membrane antigen–positron emission tomography/computed tomography (68Ga-PSMA-PET/CT). Subjects/patients and methods: A 68-year-old male with a prostate adenocarcinoma presented with testicular metastasis. The patient was diagnosed with 68Ga-PSMA-PET/CT, and bilateral inguinal orchiectomy was performed. Herein, our case is presented, and a short review of the literature is carried out. Conclusion: 68Ga-PSMA-PET/CT is an effective imaging method for detecting rare metastases. Level of evidence: 4

scholarly journals Can 68Ga-prostate specific membrane antigen positron emission tomography/computerized tomography provide an accurate lymph node staging for patients with medium/high risk prostate cancer? A diagnostic meta-analysis

2020 ◽  
Vol 15 (1) ◽  
Author(s):  
Lei Peng ◽  
Jinze Li ◽  
Chunyang Meng ◽  
Jinming Li ◽  
Chengyu You ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Positron Emission Tomography ◽  
Lymph Node ◽  
High Risk ◽  
Meta Analysis ◽  
Diagnostic Value ◽  
Emission Tomography ◽  
Positron Emission ◽  
Psma Pet ◽  
Pet Ct

Abstract Objective This article aims to evaluate the diagnostic value of 68Gallium-PSMA positron emission tomography/computerized tomography (68Ga-PSMA PET/CT) for lymph node (LN) staging in patients with prostate cancer (PCa) by a meta-analysis of diagnostic tests. Methods We systematically retrieved articles from Web of Science, EMBASE, Cochrane Database, PubMed. The time limit is from the creation of the database until June 2019, and Stata 15 was used for calculation and statistical analyses. Results Sensitivity, specificity, positive and negative likelihood ratio (PLR, NLR), diagnostic odds ratio (DOR) and 95% confidence intervals (CI) be used to evaluate the diagnostic value. A total of 10 studies were included in our meta-analysis, which included 701 individuals. The results of each consolidated summary are as follows: sensitivity of 0.84 (95% CI 0.55–0.95), specificity of 0.95 (95% CI 0.87–0.98), PLR and NLR was 17.19 (95% CI 6.27, 47.17) and 0.17 (95% CI 0.05–0.56), respectively. DOR of 100 (95% CI 18–545), AUC of 0.97 (95% CI 0.95–0.98). Conclusion Our study demonstrates that 68Ga-PSMA PET/CT has a high overall diagnostic value for LN staging in patients with moderate and high-risk PCa. But our conclusions still require a larger sample size, multi-center prospective randomized controlled trial to verify.

scholarly journals Comparison of 68Ga-PSMA-11 PET/CT with 11C-acetate PET/CT in re-staging of prostate cancer relapse

2020 ◽  
Vol 10 (1) ◽  
Author(s):  
Naresh Regula ◽  
Vasileios Kostaras ◽  
Silvia Johansson ◽  
Carlos Trampal ◽  
Elin Lindström ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Specific Antigen ◽  
Anatomical Location ◽  
Curative Therapy ◽  
Psa Relapse ◽  
Positron Emission ◽  
Psma Pet ◽  
Pet Ct ◽  
Prostate Cancer Relapse ◽  
Identical Number

AbstractPositron emission tomography (PET) imaging is used to localize recurrent disease in prostate cancer (PCa). The tracer 68Ga-PSMA-11 visualizes lesions overexpressing prostate-specific membrane antigen (PSMA), while 11C-acetate visualizes lesions with increased anabolic metabolism. The aim of this study was to compare the performance of PSMA-PET and acetate-PET in re-staging patients with biochemical relapse. Thirty PCa patients with prostate-specific antigen (PSA) relapse after primary curative therapy were prospectively evaluated. PET/CT examinations using 11C-acetate and 68Ga-PSMA-11 were performed. Identified lesions were categorized according to anatomical location and PET measurements were correlated with PSA at time of scan. Tumour lesions showed higher semi-quantitative uptake values on PSMA-PET than acetate-PET. PSMA-PET identified more lesions in 11 patients, fewer lesions in eight patients, and identical number of lesions in 11 patients. This study indicates better diagnostic performance of PSMA-PET, particularly in detecting lymph node (81% vs 60%, p = 0.02) and bone metastasis (95% vs 61%, p = 0.0001) compared to acetate-PET. However, 38% of PSMA-expressing metastases appear to be metabolically inactive and 15% of metabolically active metastases lack PSMA expression. Addition of PET with a metabolic tracer, such as 11C-acetate, might be beneficial before making treatment decisions.

scholarly journals Non-Prostate Cancer Tumours: Incidence on 18f-Dcfpyl Psma Pet/Ct and Psma Expression Characteristics in 1445 Patients.

2021 ◽  
Author(s):  
Elisa Perry ◽  
Arpit Talwar ◽  
Sanjana Sharma ◽  
Daisy O'Connor ◽  
Lih-Ming Wong ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Second Primary ◽  
Public And Private ◽  
Histopathological Correlation ◽  
Positron Emission ◽  
Psma Pet ◽  
Pet Ct ◽  
Second Primary Malignancies ◽  
Clinical Dilemma ◽  
Psma Expression

Abstract PurposeProstate cancer (PCa) imaging has been revolutionized by Positron emission tomography (PET) tracers targeted to prostate specific membrane antigen (PSMA). Identification and characterization of non-PCa tumors has become an increasing clinical dilemma with growing use. The primary aim of this retrospective multicenter analysis was to determine atypical PSMA expression in PCa and expression in non-PCa tumors to aid providing clinically relevant reports and guiding multidisciplinary discussion.MethodsRetrospective multicenter study examining 1445 consecutive 18F-DCFPyL PSMA PET/CT between 2016-2020. Referrals were from public and private, secondary and tertiary referral centres serving New Zealand and Melbourne. Repeat studies were excluded. Lesions atypical for PCa were categorized into four groups: 1. Atypical PCa metastases 2. Non-PCa tumors 3. Benign and 4. Indeterminate.Results67 patients had lesions atypical for PCa metastases; 11.9% atypical prostate cancer metastases, 25.4% non-PCa tumors, 40.3% indeterminate, 10.4% benign. With the exception of Renal Cell Carcinoma (RCC), the non-PCa tumors, indeterminate and benign lesions demonstrated low PSMA expression. Most atypical PCa metastases demonstrated significant expression. Limitations included retrospective design and lack of histopathological correlation/follow up in some.Conclusions: Non-PCa tumor detection is low. Lesions demonstrating significant PSMA expression were almost exclusively PCa metastases. Differentiation of atypical PCa metastases from second primary malignancies is vital to avoid unnecessary investigation, delayed therapy and additional costs.

scholarly journals Metabolic Tumour Volume from PSMA PET/CT Scans of Prostate Cancer Patients during Chemotherapy—Do Different Software Solutions Deliver Comparable Results?

2020 ◽  
Vol 9 (5) ◽  
pp. 1390
Author(s):  
Philipp E. Hartrampf ◽  
Marieke Heinrich ◽  
Anna Katharina Seitz ◽  
Joachim Brumberg ◽  
Ioannis Sokolakis ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Therapy Response ◽  
Tumour Volume ◽  
Ct Scans ◽  
Metabolic Tumour Volume ◽  
Positron Emission ◽  
Psma Pet ◽  
Pet Ct ◽  
Before And After ◽  
Statistical Comparability

(1) Background: Prostate-specific membrane antigen (PSMA)-derived tumour volume (PSMA-TV) and total lesion PSMA (TL-PSMA) from PSMA PET/CT scans are promising biomarkers for assessing treatment response in prostate cancer (PCa). Currently, it is unclear whether different software tools for assessing PSMA-TV and TL-PSMA produce comparable results. (2) Methods: 68Ga-PSMA PET/CT scans from n = 21 patients with castration-resistant PCa (CRPC) receiving chemotherapy were identified from our single-centre database. PSMA-TV and TL-PSMA were calculated with Syngo.via (Siemens) as well as the freely available Beth Israel plugin for FIJI (Fiji Is Just ImageJ) before and after chemotherapy. While statistical comparability was illustrated and quantified via Bland-Altman diagrams, the clinical agreement was estimated by matching PSMA-TV, TL-PSMA and relative changes of both variables during chemotherapy with changes in serum PSA (ΔPSA) and PERCIST (Positron Emission Response Criteria in Solid Tumors). (3) Results: Comparing absolute PSMA-TV and TL-PSMA as well as Bland–Altman plotting revealed a good statistical comparability of both software algorithms. For clinical agreement, classifying therapy response did not differ between PSMA-TV and TL-PSMA for both software solutions and showed highly positive correlations with BR. (4) Conclusions: due to the high levels of statistical and clinical agreement in our CRPC patient cohort undergoing taxane chemotherapy, comparing PSMA-TV and TL-PSMA determined by Syngo.via and FIJI appears feasible.

scholarly journals Combined Intravenous Urogram and 68Ga-PSMA PET/ CT for Improved Staging and Restaging of Prostate Cancer

2020 ◽  
Vol 10 ◽  
pp. 67
Author(s):  
Rhiannon McBean ◽  
Anisa Kumari ◽  
Louise McEwan ◽  
James Walters ◽  
David Wong
Keyword(s):  
Prostate Cancer ◽  
Imaging Protocol ◽  
Intravenous Urogram ◽  
Positron Emission ◽  
Psma Pet ◽  
Pet Ct ◽  
Imaging Approach ◽  
Pictorial Essay ◽  
Gallium 68 ◽  
Specific Membrane

Staging/restaging of prostate cancer utilizing Gallium-68 (68Ga) prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) in combination with an intravenous urogram allows improved discrimination between radiotracer activity in the renal tract and small pelvic nodes or local recurrences. Within this pictorial essay, we describe the imaging protocol utilized at our institution and present cases which demonstrate the utility of this combined imaging approach.

scholarly journals Evaluation of 18F-DCFPyL PSMA PET/CT for Prostate Cancer: A Meta-Analysis

2021 ◽  
Vol 10 ◽  
Author(s):  
Ke-Hao Pan ◽  
Jin-Feng Wang ◽  
Chun-Ying Wang ◽  
Abdul Aziz Nikzad ◽  
Fang Q. Kong ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Meta Analysis ◽  
Inclusion Criteria ◽  
Ct Diagnosis ◽  
Clinical Value ◽  
Positron Emission ◽  
Psma Pet ◽  
Pet Ct ◽  
Specific Membrane

BackgroundTo systematically review the clinical value of 18F-DCFPyL prostate-specific membrane antigen positron emission tomography/computed tomography (PSMA PET/CT) in the diagnosis of prostate cancer (PCa).MethodsLiterature concerning 18F-DCFPyL PSMA PET/CT in the diagnosis of prostate cancer published from 2015 to 2020 was electronically searched in the databases including PubMed and Embase. Statistical analysis was carried out with STATA 15 software, and the quality of included studies was tested with quality assessment of diagnostic accuracy studies (QUADAS) items. The heterogeneity of the included data was tested.ResultsIn total, nine pieces of literature involving 426 patients met the inclusion criteria. The heterogeneity of the study group was not obvious. The SEN, SPE, LR+, LR−, DOR as well as AUC of 18F-DCFPyL PSMA PET/CT diagnosis of prostate cancer were 0.91, 0.90, 8.9, 0.10, 93, and 0.93. The pooled DR of 18F-DCFPyL labeled PSMA PET/CT in PCa was 92%. The pooled DR was 89% for PSA≥0.5 ng/ml and 49% for PSA < 0.5ng/ml.Conclusion18F-DCFPyL PSMA PET/CT had good sensitivity and specificity for the diagnosis of prostate cancer. The DR of 18F-DCFPyL PSMA PET/CT was correlated with PSA value. Further large-sample, high-quality studies were needed.

PSMA-PET/CT-avid metastatic prostate cancer to the penis

2020 ◽  
Vol 13 (3) ◽  
pp. e233522
Author(s):  
Margaret Mary Mansbridge ◽  
Andrew Strahan ◽  
Jonathon Parker ◽  
Handoo Rhee
Keyword(s):  
Prostate Cancer ◽  
External Beam Radiotherapy ◽  
Locally Advanced ◽  
Penile Metastasis ◽  
Positron Emission ◽  
Psma Pet ◽  
Pet Ct ◽  
Malignant Priapism ◽  
Specific Membrane ◽  
Penile Metastases

Penile metastases from prostate cancer (PC) are rarely reported in the literature. Most commonly diagnosed due to presentation with malignant priapism and other urinary symptoms or from findings on clinical examination, prognosis has been reported to be poor. The authors outline a case of penile metastasis from advanced PC. Initially treated with neoadjuvant androgen deprivation therapy for locally advanced PC, this patient displayed upfront castrate resistance, and subsequent prostate-specific membrane antigen positron emission tomography revealed penile metastatic deposits. The patient was treated with external beam radiotherapy, and worsening urethral stricture disease resulted in the placement of a suprapubic catheter.

Sign in / Sign up

Export Citation Format

Share Document